185 related articles for article (PubMed ID: 35921987)
21. Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
Ohta T; Sugio Y; Imanaga H; Oku S; Ohno Y
Int J Hematol; 2019 Sep; 110(3):347-354. PubMed ID: 31197737
[TBL] [Abstract][Full Text] [Related]
22. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
[TBL] [Abstract][Full Text] [Related]
23. [The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Tang B; Zheng C; Liu H; Zhu X; Geng L; Wang X; Ding K; Yao W; Tong J; Song K; Zhang L; Qiang P; Zhang X; Sun Z
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):191-5. PubMed ID: 26926370
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.
Arai Y; Aoki K; Takeda J; Kondo T; Eto T; Ota S; Hashimoto H; Fukuda T; Ozawa Y; Kanda Y; Kato C; Kurokawa M; Iwato K; Onizuka M; Ichinohe T; Atsuta Y; Takami A;
J Hematol Oncol; 2015 Sep; 8():102. PubMed ID: 26337829
[TBL] [Abstract][Full Text] [Related]
25. Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Hirabayashi S; Uozumi R; Kondo T; Arai Y; Kawata T; Uchida N; Marumo A; Ikegame K; Fukuda T; Eto T; Tanaka M; Wake A; Kanda J; Kimura T; Tabuchi K; Ichinohe T; Atsuta Y; Yanada M; Yano S
Cancer Med; 2021 Jul; 10(13):4250-4268. PubMed ID: 34132501
[TBL] [Abstract][Full Text] [Related]
26. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
27. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.
Sun Z; Liu H; Luo C; Geng L; Zheng C; Tang B; Zhu X; Tong J; Wang X; Ding K; Wan X; Zhang L; Yao W; Song K; Zhang X; Wu Y; Yang H; Han Y; Liu X; Zhu W; Wu J; Wang Z
Int J Cancer; 2018 Aug; 143(3):699-708. PubMed ID: 29473150
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Kamijo K; Shimomura Y; Shinohara A; Mizuno S; Kanaya M; Usui Y; Kim SW; Ara T; Mizuno I; Kuriyama T; Nakazawa H; Matsuoka KI; Kusumoto S; Maseki N; Yamaguchi M; Ashida T; Onizuka M; Fukuda T; Atsuta Y; Kondo E
Ann Hematol; 2023 Mar; 102(3):651-661. PubMed ID: 36631705
[TBL] [Abstract][Full Text] [Related]
29. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
Devillier R; Galimard JE; Labopin M; Blaise D; Raiola AM; Pavlu J; Castagna L; Socié G; Chalandon Y; Martino M; Stölzel F; Bug G; Bruno B; Vrhovac R; Charbonnier A; Olivieri A; Bay JO; Arroyo H; Yakoub-Agha I; Avenoso D; Neubauer A; Nguyen S; Forcade E; Brissot E; Savani B; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Sep; 57(9):1421-1427. PubMed ID: 35752739
[TBL] [Abstract][Full Text] [Related]
30. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
[TBL] [Abstract][Full Text] [Related]
31. Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
Kurita N; Imahashi N; Chiba S; Tanaka M; Kobayashi H; Uchida N; Kuriyama T; Anzai N; Nawa Y; Nakano N; Ara T; Onizuka M; Katsuoka Y; Koi S; Kimura T; Ichinohe T; Atsuta Y; Kanda J;
Am J Hematol; 2024 Feb; 99(2):236-244. PubMed ID: 38165068
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.
Konuma T; Ooi J; Nagayama H; Tomonari A; Tsukada N; Kato S; Kawakita T; Isobe M; Monna-Oiwa M; Tojo A; Iseki T; Takahashi S
Ann Hematol; 2022 Jan; 101(1):177-189. PubMed ID: 34591162
[TBL] [Abstract][Full Text] [Related]
33. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Yamashita T; Takami A; Uchida N; Fukuda T; Eto T; Shiratori S; Ota S; Akasaka T; Miyakoshi S; Kondo T; Hidaka M; Kanda J; Atsuta Y; Yano S
Bone Marrow Transplant; 2020 Oct; 55(10):1955-1965. PubMed ID: 32203256
[TBL] [Abstract][Full Text] [Related]
34. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
[TBL] [Abstract][Full Text] [Related]
35. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
Tang W; Fan X; Wang L; Hu J
Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
[TBL] [Abstract][Full Text] [Related]
36. Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms.
Nakamura Y; Tanaka Y; Tanaka M; Yamamoto K; Matsuguma M; Kajimura Y; Tokunaga Y; Yujiri T; Tanizawa Y
Transplant Proc; 2019 Apr; 51(3):896-900. PubMed ID: 30979482
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
38. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
39. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
Giebel S; Labopin M; Socié G; Aljurf M; Salmenniemi U; Labussière-Wallet H; Srour M; Kröger N; Zahrani MA; Lioure B; Reményi P; Arat M; Bourhis JH; Helbig G; Tbakhi A; Forcade E; Huynh A; Brissot E; Spirydonidis A; Savani BN; Peric Z; Nagler A; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):506-513. PubMed ID: 36725978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
